In contrast, 2 randomized controlled trials in unhealthy adults, 1 in participants with coronary artery disease and the second in patients undergoing gastric bypass surgery, demonstrate that supplementation for 12 wk with 1.6 × 109 CFU/d of Lactobacillus rhamnosus GG or 16 wk with >1010 CFU/d of a multi-stain probiotic containing Lactobacillus, Streptococcus, and Bifidobacterium significantly decreased serum LPS and LBP compared to controls [98,99]. The gene discussed is LBP; the disease is coronary artery disorder.